Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490795 | 0.89 | CTPS1 (0.69) | CTPS1 | |
| SCHEMBL30528846 | 0.84 | CTPS1 (0.55) | CTPS1 | |
| SCHEMBL22491722 | 0.84 | CTPS1 (0.55) | CTPS1 | |
| SCHEMBL22490782 | 0.83 | CTPS1 (0.64) | CTPS1 | |
| SCHEMBL22490757 | 0.82 | CTPS1 (0.49) | CTPS1 | |
| SCHEMBL22491743 | 0.81 | CTPS1 (0.63) | CTPS1 | |
| SCHEMBL22491634 | 0.81 | CTPS1 (0.63) | CTPS1 | |
| SCHEMBL22491633 | 0.81 | CTPS1 (0.63) | CTPS1 | |
| SCHEMBL21044097 | 0.81 | CTPS1 (0.65) | CTPS1 | |
| SCHEMBL26677376 | 0.81 | CTPS1 (0.71) | CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | claimed |
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4637770-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | Step Pharma S.A.S. (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| US-20250177394-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S A S (FR) | 2025-06-05 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-4486347-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | Step Pharma S.A.S. (FR) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024133730-A1 | CTPS1 INHIBITORS FOR USE IN THE TREATMENT OF CTPS2 DEFICIENT CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024133721-A1 | COMBINATIONS OF CTPS1 INHIBITOR WITH IAP INHIBITOR FOR USE IN THE TREATMENT OF CANCER | STEP PHARMA S.A.S. (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023166076-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166080-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A WEE1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166078-A1 | COMBINATION TREATMENTS COMPRISING A CTPS1 INHIBITOR AND A CHEK1 INHIBITOR | STEP PHARMA S.A.S. (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-11505547-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2022-11-22 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |
| EP-3717465-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885 |
| US-11505547-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885 |
| US-20250177394-A1 | COMBINATIONS OF CTPS1 AND BCL2 INHIBITORS FOR CANCER | CTPS1, CTPS2, TYMS | CTPS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.